Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7839019 | 0.89 | PPARG (0.42) | PPARGCYP3A4RXRAHPGDKCNH2 | |
| SCHEMBL8196247 | 0.89 | PPARG (0.42) | PPARGCYP3A4RXRAHPGDKCNH2 | |
| SCHEMBL7879357 | 0.86 | KCNH2 (0.40) | PPARGCYP3A4RXRAKCNH2 | |
| SCHEMBL163917 | 0.85 | PPARG (0.66) | PPARGCYP3A4RXRAHPGDHRH3 | |
| SCHEMBL8791799 | 0.84 | HPGD (0.54) | PPARGCYP3A4RXRAHPGDHRH3 | |
| SCHEMBL1220739 | 0.84 | PPARG (0.48) | PPARGCYP3A4RXRAHPGDHRH3 | |
| Hydrochloric Acid SCHEMBL2944707 | 0.84 | PPARG (0.66) | PPARGCYP3A4RXRAHPGDHRH3 | |
| SCHEMBL9311838 | 0.82 | FFAR1 (0.43) | PPARGCYP3A4RXRAFFAR1 | |
| SCHEMBL1220653 | 0.81 | PPARG (0.43) | PPARGCYP3A4RXRAHPGDHRH3 | |
| SCHEMBL8791594 | 0.81 | PPARG (0.41) | PPARGCYP3A4RXRAHPGDKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842706-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | claimed |
| US-20090246232-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2009-10-01 | — | — | US | claimed |
| US-6329404-B1 | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | claimed |
| US-6172089-B1 | 2,4-THIADOLIDINEDIONE INSULIN SENSITIVITY ENHANCER MIXTURE WITH ANGIOTENSIN CONVERTING ENZYME INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| US-6133293-A | INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | claimed |
| US-5965584-A | insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-12 | — | — | US | claimed |
| US-4687777-A | pioglitazone and salts | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-18 | — | — | US | claimed |
| US-11021751-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190032137-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8846315-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2012096680-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20110166185-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. | 2011-07-07 | — | — | US | disclosed |
| EP-0953355-A1 | REMEDY FOR AUTOIMMUNE DISEASES | Sankyo Company, Limited (JP) | 1999-11-03 | — | — | EP | disclosed |
| US-5965584-A | insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0861666-A2 | Pharmaceutical composition for use in treatment of diabetes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0749751-A2 | Pharmaceutical composition for use in tteatment of diabetes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0193256-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4687777-A | pioglitazone and salts | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-18 | — | — | US | disclosed |
| EP-0193256-A1 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246232-A1 | Pharmaceutical composition | GPR119, IAPP, INSR | PPARG 19/4885CYP3A4 389/4885RXRA 1384/4885 |
| US-20110166185-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | PPARG 1229/4885CYP3A4 1186/4885RXRA 2219/4885 |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | PPARG 1229/4885CYP3A4 1186/4885RXRA 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.